This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I23 (complications following acute myocardial infarction) | Special Copayment Reduction: V192 (Special Copayment Reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Mechanical complications of myocardial infarction, post-infarction complications, post-MI mechanical complication, STEMI/NSTEMI complications |
| C. Adult onset | A group of mechanical, electrical and thrombotic complications occurring within 28 days of acute myocardial infarction, presenting mainly in middle age and later; a clinical emergency that strongly influences mortality even today, when reperfusion therapy is widespread. |
| 1. History | History of complication management, beginning with early 20th-century pathological descriptions and progressing through the introduction of coronary care units and the reperfusion era to the current era of mechanical circulatory support devices |
| 2. Causes | Extensive myocardial necrosis, delayed reperfusion, older age, diabetes, anterior wall infarction and multivessel disease are the main risk factors that increase the occurrence of mechanical complications |
| 3. Genetics | Genetic variants related to the extracellular matrix, such as COL1A1 and COL3A1, influence susceptibility to myocardial rupture, and associations with MMP gene polymorphisms have also been reported |
| 4. General epidemiology | Incidence of mechanical complications about 5–10% before the reperfusion era and about 1–3% now, but still a leading cause of death after infarction |
| 5. Pathophysiology | Structural fragility of necrotic myocardium, ventricular remodeling, extracellular matrix degradation by infiltrating inflammatory cells and myocardial rupture, and mechanisms of thrombus formation |
| 6. Symptoms | Sudden hemodynamic deterioration, dyspnea, recurrent chest pain and symptoms of cardiogenic shock appear abruptly or gradually depending on the type of complication |
| 7. Signs | New heart murmurs, jugular venous distension, auscultatory signs of pulmonary edema, pericardial friction rub, hypotension and signs of peripheral circulatory failure appear specifically for each complication |
| 8. Screening | 12-lead ECG, cardiac enzymes (troponin, BNP) and echocardiography play key roles in initial screening for acute complications |
| 9. Diagnosis | Type and severity of complications confirmed by transthoracic and transesophageal echocardiography, cardiac CT, MRI and hemodynamic measurement with a Swan-Ganz catheter |
| 10. Treatment | Mechanical circulatory support (IABP, Impella, ECMO), emergency surgery (closure of ventricular septal defect, repair of myocardial rupture, valvuloplasty), with concurrent antithrombotic therapy |
| 11. Prognosis | In-hospital mortality of cardiogenic shock with mechanical complications 40–80%; prognosis can improve with early surgery and mechanical support |
| 12. Prevention | Rapid reperfusion (door-to-balloon <90 minutes), risk factor management and optimization of antiplatelet and anticoagulant therapy are key to reducing the incidence of complications |
| 13. References | Mechanical complications of acute myocardial infarction: a scientific statement from the American Heart Association … and 9 other papers |
The history of complications after acute myocardial infarction parallels the development of cardiology. After James Bryan Herrick first systematically described the clinical link between coronary thrombosis and myocardial infarction in 1912 in the early 20th century, pathologists began to describe necrosis, rupture and mechanical complications of post-infarction myocardial tissue from autopsy findings. In the 1930s–1940s, ventricular free wall rupture and ventricular septal defect were pathologically confirmed as major causes of death after acute myocardial infarction, but at the time there were almost no means of therapeutic intervention.
The introduction of coronary care units (CCU) in the 1960s revolutionized the management of patients with myocardial infarction. As continuous ECG monitoring and immediate treatment of arrhythmias became possible, mortality from electrical complications fell greatly. However, deaths from mechanical complications remained high. In 1969 Mundth et al. reported a case of surgical repair performed after hemodynamic stabilization with an intra-aortic balloon pump (IABP) in a patient with ventricular septal rupture, first demonstrating the feasibility of surgical treatment.
In the 1970s–1980s, the advent of thrombolytic agents opened a new era of reperfusion therapy. The GISSI-1 study (1986) and the ISIS-2 study (1988) showed that thrombolytic therapy could reduce infarct size and the occurrence of mechanical complications. During this period, echocardiography spread into clinical practice, making noninvasive real-time diagnosis of mechanical complications possible, which contributed to dramatically improved treatment outcomes.
Since the 1990s, the spread of percutaneous coronary intervention (PCI), especially primary PCI, has greatly lowered the incidence of mechanical complications. The PAMI study (1993) and subsequent large randomized controlled trials demonstrated that primary PCI produces superior outcomes compared with thrombolytic therapy. Shortening the time to reperfusion (door-to-balloon time <90 minutes) is estimated to have reduced the occurrence of mechanical complications by more than 50%.
Since the 2000s, advances in percutaneous mechanical circulatory support (MCS) devices such as Impella, TandemHeart and VA-ECMO have changed the treatment paradigm for patients with cardiogenic shock and mechanical complications. The 2023 ESC acute coronary syndrome guidelines emphasize a strategy of early MCS insertion followed by stabilization in shock with mechanical complications, and state that for ventricular septal rupture, outcomes improve when surgery is performed at least 7 days after the infarction. Currently, advances in transcatheter valve procedures and percutaneous closure of ventricular septal defects are expanding new treatment options even for patients at high surgical risk.
The occurrence of complications after acute myocardial infarction is closely related to various clinical risk factors. The most important causal factor is extensive myocardial necrosis. Anterior myocardial infarction, especially large infarctions due to proximal occlusion of the left anterior descending artery (LAD), is the main substrate for mechanical complications such as ventricular free wall rupture, ventricular septal defect and papillary muscle rupture. Necrotic myocardial tissue loses its structural strength and, in this process, cannot withstand mechanical load, so rupture occurs.
Delayed reperfusion is an important cause of mechanical complications. When reperfusion occurs more than 12 hours after symptom onset or complete reperfusion fails, the extent of necrosis in the infarcted myocardium expands and the risk of complications increases. Conversely, excessively early reperfusion may cause reperfusion injury and hemorrhagic transformation, but overall, early reperfusion is favorable for preventing mechanical complications.
Important demographic and systemic risk factors include older age (especially 75 and over), female sex, diabetes, chronic kidney disease and hypertension. Older patients have a reduced capacity for myocardial extracellular matrix remodeling and thus a higher risk of rupture. In diabetic patients, microvascular lesions result in insufficient collateral development, and myocardial healing after infarction may be delayed. Patients who received thrombolytic therapy as initial treatment, especially with incomplete reperfusion, also tend to have a higher incidence of mechanical complications than the primary PCI group.
Characteristics of the infarct-related artery are also important. In single-vessel disease without developed collateral circulation, the initial infarct size is large and the risk of complications is high. Conversely, even in multivessel disease, some protective effect can be expected when collateral circulation has developed to a vessel with chronic total occlusion. An infarct-related artery with a high thrombus burden can cause the no-reflow phenomenon and enlarge the infarct.
There are also complication-specific causes corresponding to the subcodes of ICD I23. Hemopericardium (I23.0) is due to ventricular free wall rupture or traumatic pericardial bleeding; ventricular septal defect (I23.2) results from transmural necrosis of the ventricular septum in anterior infarction; and papillary muscle rupture (I23.5) results from the vulnerability of the single-vessel supply to the posteromedial papillary muscle in inferior infarction. Atrial and ventricular thrombi (I23.6) form in dyskinetic infarct areas through the combined action of blood stasis and endothelial injury.
An individual's genetic background may play an important role in the occurrence of mechanical complications after acute myocardial infarction. Because mechanical complications such as myocardial rupture are directly related to the structural integrity of myocardial tissue, variants in genes encoding extracellular matrix (ECM) components have drawn particular attention. Studies have reported associations between single nucleotide polymorphisms (SNPs) in the COL1A1, COL1A2 and COL3A1 genes, which are involved in collagen structure and synthesis, and myocardial fragility.
Polymorphisms in the matrix metalloproteinase (MMP) gene family may also be associated with post-infarction mechanical complications. MMP-1, MMP-2 and MMP-9 mediate ECM degradation during the inflammatory response after myocardial infarction, and overactivation of these enzymes is associated with ventricular free wall rupture and worsening ventricular remodeling. There are reports that the -1562C>T polymorphism of the MMP-9 gene is associated with ventricular dilatation after infarction.
Genes related to the inflammatory response also influence the occurrence of complications. The -308G>A polymorphism of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) gene polymorphisms are associated with an excessive inflammatory response after infarction and may aggravate damage to myocardial tissue. Platelet glycoprotein receptor genes (GPIIIa PlA1/A2 polymorphism) influence thrombotic tendency and may be associated with the development of ventricular thrombus.
Coagulation-related genes involved in ventricular thrombus formation (I23.6) are also important. Genetic variants related to inherited thrombophilia, such as the factor V Leiden mutation, the prothrombin G20210A mutation and the MTHFR C677T polymorphism, can increase the risk of post-infarction ventricular thrombus and systemic thromboembolism. In patients with such a genetic background, additional consideration of the intensity and duration of anticoagulation is needed.
Apolipoprotein E (ApoE) genotype affects the severity of coronary artery disease and infarct size and is thus indirectly associated with the risk of mechanical complications. Carriers of the ApoE ε4 allele tend to have faster progression of atherosclerosis and larger infarcts, so their risk of complications may be relatively higher. However, no single genetic marker specific to mechanical complications after acute myocardial infarction has yet been established, and clinical risk factors act as stronger predictors than genetic factors.
The incidence of mechanical complications after acute myocardial infarction has fallen markedly since reperfusion therapy became widespread. In the pre-thrombolytic era (before the 1970s), mechanical complications occurred in about 10% of patients with myocardial infarction and were a major cause of in-hospital death. Since the spread of primary PCI in the 1990s, the overall incidence of mechanical complications has fallen greatly to about 1–3%, but when complications occur, in-hospital mortality remains very high.
Ventricular septal rupture (VSR) occurs in about 0.17–0.31% of acute myocardial infarctions, compared with about 1–2% in the pre-reperfusion era. Its incidence peaks mainly on days 3–5 after infarction, but in the reperfusion era it tends to occur earlier as well (days 1–2). In-hospital mortality reaches 90% without surgical treatment and 40–50% even after surgery.
Ventricular free wall rupture occurs in about 0.32–0.45% of acute myocardial infarctions, most frequently within the first 1–5 days after infarction. The risk is high in older patients, women, anterior infarction and patients who did not receive reperfusion therapy. Most free wall ruptures are of the acute type with death within minutes, but in subacute rupture, temporary sealing by fibrin or thrombus occurs, and it is sometimes found in the form of pericardial effusion or pseudoaneurysm.
Severe mitral regurgitation due to acute papillary muscle rupture occurs in about 0.26% of acute myocardial infarctions. It occurs more often in inferior infarction because of the structural characteristic that the posteromedial papillary muscle is supplied by a single vessel (right coronary artery or left circumflex artery). Like ventricular septal rupture, it is accompanied by rapid hemodynamic deterioration and high mortality.
The incidence of ventricular thrombus (I23.6) is reported in 10–15% of patients with anterior STEMI and is particularly high in apical infarction with wall motion abnormality. Without appropriate anticoagulation, it causes systemic embolism (including stroke). Hemopericardium (I23.0) occurs as an accompanying finding of free wall rupture and leads to cardiac tamponade, requiring immediate treatment. In Korea, according to Health Insurance Review & Assessment Service (HIRA) data, the incidence of mechanical complications in STEMI patients is improving to levels similar to those of developed countries.
The pathophysiology of mechanical complications after acute myocardial infarction can be understood as the sequential process of ischemic myocardial necrosis → inflammatory response → extracellular matrix degradation → acquisition of structural fragility. Ischemia begins within minutes of coronary occlusion, and irreversible myocardial necrosis begins within 20–40 minutes. Necrotic cardiomyocytes lose membrane integrity and release intracellular enzymes and inflammatory mediators.
In the necrotic myocardium, neutrophils infiltrate within the first 6–12 hours and begin clearing necrotic tissue. In this process, large amounts of matrix metalloprotease (MMP)-9, elastase, collagenase and the like are released, degrading the collagen fiber network of the myocardial extracellular matrix. As a result, the "softening" phase, in which the structural strength of the infarcted myocardium falls sharply, peaks on days 3–5 after infarction, and this is the peak period for mechanical complications.
Ventricular septal rupture (VSR) occurs in anterior infarction involving the anterior septum (LAD occlusion) or inferior infarction involving the posterior septum (right coronary artery occlusion). The mechanism is perforation of the softened myocardial tissue of the infarcted septum under the continuous pressure difference between the left and right ventricles (left ventricular systolic pressure about 120mmHg vs. right ventricular systolic pressure about 25mmHg). The perforation is more often simple in anterior infarction and serpiginous/complex in inferior infarction.
Free wall rupture occurs when intraventricular pressure is continuously applied to softened infarcted myocardium. A tear progresses from the endocardium toward the epicardium, and acute bleeding into the pericardial space causes hemopericardium and cardiac tamponade. In subacute rupture, the tissue may be temporarily sealed by fibrin and clot, forming a false aneurysm.
Papillary muscle rupture results from complete or partial necrosis of a papillary muscle, and the resulting loss of mitral support structures causes acute severe mitral regurgitation. Ventricular thrombus formation results from the combined action of endothelial injury of the endocardium in the infarct area, blood stasis (ventricular wall motion abnormality) and a hypercoagulable state (Virchow's triad). In apical infarction, stasis within the left ventricular apex is particularly severe, so thrombus forms easily.
The symptoms of complications after acute myocardial infarction vary with the type and severity of the complication, and most are accompanied by sudden, serious hemodynamic changes. Commonly, the most important symptom is sudden hemodynamic deterioration, which can progress to cardiogenic shock within minutes to hours.
In ventricular septal rupture (VSR), sudden dyspnea, chest pain and a rapid fall in blood pressure are the main symptoms. Even if symptoms are relatively mild initially, they can worsen to pulmonary edema and cardiogenic shock within hours. Patients complain of severe fatigue and anxiety, with cold and pale extremities.
In hemopericardium due to ventricular free wall rupture, the acute type leads to loss of consciousness within minutes and progresses to electromechanical dissociation (pulseless electrical activity, PEA), mostly resulting in immediate death. In the subacute type, recurrent chest pain, a sudden fall in blood pressure, bradycardia and chest discomfort may appear, and symptoms of cardiac tamponade (Beck's triad: hypotension, jugular venous distension, muffled heart sounds) are observed.
Acute severe mitral regurgitation due to acute papillary muscle rupture is characterized by sudden pulmonary edema and severe dyspnea. Patients complain of orthopnea, feeling comfortable only in a sitting position, sometimes with pink frothy sputum. In this case, progression to cardiogenic shock is very rapid.
Ventricular thrombus (I23.6) is often asymptomatic by itself, but when the thrombus dislodges and causes cerebral embolism or peripheral arterial embolism, sudden hemiplegia, speech disturbance, visual disturbance, or limb pain and pallor occur. Atrial septal defect (I23.1) or ventricular septal defect (I23.2) may gradually produce decreased oxygen saturation due to intracardiac left-to-right shunting and symptoms of right heart failure (leg edema, jugular venous distension, ascites).
Because the clinical signs of complications after acute myocardial infarction appear specifically according to the type of complication, careful physical examination plays a decisive role in early diagnosis. The most characteristic sign of ventricular septal rupture (VSR) is a new holosystolic murmur, heard with maximal intensity at the lower left sternal border, sometimes with a palpable thrill. This murmur resembles that of acute mitral regurgitation but can be distinguished by its location and direction.
In mitral regurgitation due to acute papillary muscle rupture, a new holosystolic or late systolic murmur is best heard at the apex and may radiate to the axilla. The intensity of the murmur does not necessarily reflect the severity of regurgitation, and in severe acute regurgitation the murmur may instead be soft or absent. Bilateral moist pulmonary crackles reflecting severe pulmonary congestion are heard.
In cardiac tamponade, Beck's triad (hypotension, jugular venous distension, muffled heart sounds) is the classic sign. Pulsus paradoxus (a fall in systolic blood pressure of 10mmHg or more on inspiration) is an important sign of cardiac tamponade but is difficult to measure in severe hypotension. Weakening or absence of the apical impulse (PMI) is observed.
Common signs of cardiogenic shock include systolic blood pressure below 90mmHg, increased heart rate, weak peripheral pulses, cold extremities and cyanosis, decreased consciousness and reduced urine output. Elevated jugular venous pressure (JVP) suggests right ventricular failure or cardiac tamponade, and a gallop rhythm (S3 or S4 gallop) may be heard. As signs of pulmonary edema, moist crackles are heard at both bases, and in severe cases throughout the lung fields.
In embolism due to ventricular thrombus, focal unilateral neurological deficits are observed with cerebral embolism, and pallor, coldness, pain and pulselessness of the affected limb with peripheral arterial embolism. There are no specific auscultatory findings due to atrial or ventricular thrombus itself, but signs of accompanying ventricular dysfunction are observed.
Screening for early detection of mechanical complications in patients during or after treatment for acute myocardial infarction begins with detecting changes in clinical signs. The most basic and important screening method is continuous ECG monitoring and regular physical examination. During hospitalization, the appearance of a new heart murmur, sudden changes in blood pressure and decreased oxygen saturation are early warning signs of mechanical complications.
Serial measurement of cardiac biomarkers helps in screening for mechanical complications. Further or delayed rises in troponin I/T may suggest extension of the infarct or reinfarction. A sharp rise in B-type natriuretic peptide (BNP or NT-proBNP) indicates worsening ventricular function and increased pressure load. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can be referenced to distinguish infectious complications.
Repeated 12-lead ECGs are useful for detecting signs of reinfarction, new conduction disturbances and ventricular hypertrophy. New complete left bundle branch block, PR prolongation, or ST changes in areas other than the infarct territory suggest the possibility of complications. Low voltage raises suspicion of pericardial effusion.
Plain chest radiography is used to evaluate pulmonary vascular congestion, pulmonary edema, changes in heart size, pleural effusion and the like; sudden pulmonary edema may be seen in acute mitral regurgitation and an enlarged cardiac silhouette in pericardial effusion. However, because the sensitivity and specificity of chest X-ray are limited, echocardiography should be performed immediately when abnormalities are found.
Transthoracic echocardiography (TTE) is the most important screening and diagnostic tool for mechanical complications. It is recommended to perform it immediately on symptom onset or early in the admission of all STEMI/NSTEMI patients to evaluate ventricular function, valve function, presence of pericardial effusion and ventricular septal abnormalities, and to repeat it thereafter when the clinical condition changes. Point-of-care ultrasound (POCUS) is used as an immediate screening tool in emergencies.
Definitive diagnosis of complications after acute myocardial infarction is made mainly through imaging and hemodynamic assessment. Transthoracic echocardiography (TTE) is the key tool for initial diagnosis; in ventricular septal defect, left-to-right shunt flow can be visualized directly with color Doppler. Mitral regurgitation due to papillary muscle rupture is confirmed by a flail leaflet and an eccentric regurgitant jet, and in ventricular free wall rupture, intrapericardial effusion and blood echoes are observed.
Transesophageal echocardiography (TEE) has higher resolution than TTE and is superior for evaluating the size and location of a ventricular septal defect, the detailed valve structure, and identifying thrombi within the atria or ventricles. It is particularly essential for thrombi at sites other than the apex, assessing the extent of rupture of mitral subvalvular structures (chordae, papillary muscles) and surgical planning. It compensates for the limitations of TTE in mechanically ventilated critically ill patients or patients with poor chest wall conditions.
Cardiac magnetic resonance imaging (CMR) excels at evaluating infarct extent, ventricular function, myocardial viability and pericardial effusion, and is useful for preoperative evaluation or confirmation of subacute rupture in hemodynamically stable patients. Late gadolinium enhancement (LGE) accurately evaluates the extent of myocardial necrosis and fibrosis.
Right heart catheterization, particularly hemodynamic measurement with a Swan-Ganz catheter, is important for differentiating ventricular septal rupture from acute mitral regurgitation and assessing severity. In VSR, a stepwise increase in oxygen saturation (oxygen step-up) between the right atrium and the right ventricle or pulmonary artery is diagnostic. Large V waves on the pulmonary capillary wedge pressure (PCWP) waveform suggest acute mitral regurgitation.
Coronary angiography is essential for understanding coronary anatomy to plan treatment. When mechanical complications are confirmed, it is used to evaluate the feasibility of coronary intervention and to decide whether to perform concomitant bypass surgery (CABG) during surgical repair. Left ventriculography (LV gram) can additionally evaluate ventricular function, ventricular aneurysm and pseudoaneurysm, but caution is needed when performing it in hemodynamically unstable patients.
Treatment of mechanical complications after acute myocardial infarction requires a stepwise approach of hemodynamic stabilization → correction of the cause → recovery management. First, general measures including oxygen supply, intravenous access and continuous monitoring are performed immediately in all patients, and specific treatment is determined according to the type of complication and hemodynamic status.
Mechanical circulatory support (MCS) is the key treatment for hemodynamic stabilization in patients with mechanical complications in cardiogenic shock. The intra-aortic balloon pump (IABP) improves cardiac output by increasing aortic diastolic pressure and reducing left ventricular afterload and can be inserted percutaneously. Impella (a left ventricle–aorta pump) provides stronger hemodynamic support than IABP, and VA-ECMO is the most powerful mechanical support, supporting both pulmonary and systemic circulation. The 2023 ESC guidelines recommend a strategy of early MCS insertion followed by stabilization in shock with mechanical complications.
The definitive treatment of ventricular septal rupture (VSR) is surgical closure. However, because early surgery immediately after infarction carries a very high surgical risk owing to softened myocardial tissue, a strategy of stabilization with MCS and surgery at least 7 days later is recommended. When surgery cannot be delayed because of hemodynamic instability, emergency surgery is performed. Percutaneous ventricular septal defect closure devices (Amplatzer, etc.) may be considered in patients at high surgical risk but are not yet established as standard treatment.
For acute papillary muscle rupture, emergency surgical mitral valve replacement or repair is the only definitive treatment. Surgery is performed after hemodynamics are stabilized by inserting an IABP or Impella preoperatively. Administration of a vasodilator (nitroprusside) can temporarily improve forward cardiac output by reducing left ventricular afterload. Percutaneous catheter-based mitral valve repair (MitraClip) is being attempted in high-risk surgical patients.
Anticoagulation is the foundation of treatment for ventricular thrombus (I23.6). Initial anticoagulation is started with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH), then switched to a vitamin K antagonist (warfarin) or a direct oral anticoagulant (DOAC) and maintained for at least 3–6 months. Among DOACs, rivaroxaban has the most evidence for treating left ventricular thrombus. When the thrombus is large or mobile, increasing anticoagulation intensity or surgical removal is considered. In hemopericardium and cardiac tamponade, immediate pericardiocentesis or surgical drainage is needed.
The prognosis of mechanical complications after acute myocardial infarction varies greatly with the type and severity of the complication, the time of diagnosis and the speed of treatment. Overall, in-hospital mortality is several to tens of times higher when mechanical complications are present than when they are not.
In-hospital mortality of ventricular septal rupture (VSR) reaches 90% without surgical treatment. Even with surgical treatment, in-hospital mortality is reported at 20–50%, and the timing of surgery and the presence of cardiogenic shock are decisive for prognosis. Complex VSR associated with inferior infarction is more difficult to repair surgically and has a worse prognosis than the simple type of anterior infarction. In surviving patients, residual shunts or valve dysfunction may persist, requiring long-term follow-up.
Free wall rupture has a mortality of almost 100% in the acute type, and even in the subacute type, mortality is very high without immediate surgical treatment. Survival is possible when pericardiocentesis and emergency surgery are performed rapidly, but the overall prognosis remains poor.
In severe mitral regurgitation due to acute papillary muscle rupture, mortality within 24–48 hours without surgery is very high. Even with emergency surgery, in-hospital mortality reaches 20–40%, and the degree of preoperative hemodynamic stabilization is an important determinant of prognosis. In long-term survivors after surgery, recovery of mitral and left ventricular function affects quality of life.
Embolism from ventricular thrombus can be prevented with appropriate anticoagulation, and the prognosis of treated patients is determined by baseline ventricular function. When stroke or peripheral embolism has already occurred, the functional prognosis varies with the extent of damage. Overall, long-term survivors of acute mechanical complications are at high risk of heart failure, arrhythmia and readmission, so systematic follow-up is needed.
The most effective prevention of mechanical complications after acute myocardial infarction is minimizing infarct size through rapid and complete reperfusion. In STEMI patients, reaching a medical facility as early as possible after symptom onset and performing primary PCI with a door-to-balloon time within 90 minutes are most important. Round-the-clock catheterization laboratory operation, building an efficient emergency medical system, and improving symptom recognition through patient education are the key prevention strategies.
Optimization of antithrombotic therapy is important for complete recanalization of the infarct-related artery and prevention of rethrombosis. Dual antiplatelet therapy (DAPT: aspirin + P2Y12 inhibitor) is maintained for at least 12 months, and longer maintenance is considered in high-risk patients. Anticoagulation is actively started early in patients at high risk of ventricular thrombus formation (anterior STEMI, apical dyskinesia).
Complete revascularization can further reduce the risk of mechanical complications. In STEMI patients, there is evidence that complete revascularization, which also treats non-culprit vessels in the stable phase, reduces readmissions and cardiovascular events compared with a strategy of treating only the culprit vessel (culprit-only PCI) (COMPLETE study, 2019).
Optimization of drug therapy is also important. Beta-blockers suppress ventricular remodeling and reduce myocardial oxygen consumption, indirectly preventing complications. ACE inhibitors or ARBs suppress post-infarction ventricular remodeling and reduce the occurrence of heart failure. High-intensity statins prevent recurrent ischemia, a major cause of mechanical complications, through plaque stabilization and anti-inflammatory effects.
Risk factor management is the foundation of reinfarction prevention. Active control of blood pressure, blood glucose and blood lipids, smoking cessation, weight loss, regular exercise and participation in cardiac rehabilitation programs are recommended. In high-risk patients (extensive anterior infarction, ventricular dysfunction, diabetes), echocardiography must be performed before discharge to screen for potential complications, and the progression of ventricular remodeling should then be monitored with regular follow-up examinations.
Damluji AA, van Diepen S, Katz JN, et al. Mechanical complications of acute myocardial infarction: a scientific statement from the American Heart Association. Circulation. 2021;144(2):e16-e35. DOI: 10.1161/CIR.0000000000000985. PMID: 34126755.
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2019;40(3):237-269. DOI: 10.1093/eurheartj/ehy462. PMID: 30165617.
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2018;39(2):119-177. DOI: 10.1093/eurheartj/ehx393. PMID: 28886621.
Moreyra AE, Fenning S, Kostis JB, et al. Ventricular septal rupture complicating acute myocardial infarction: long-term outcomes and management. Journal of the American College of Cardiology. 2020;76(12):1440-1453. DOI: 10.1016/j.jacc.2020.07.055. PMID: 32943155.
Lorusso R, Whitman G, Milojevic M, et al. 2020 EACTS/ELSO/STS/AATS expert consensus on post-cardiotomy extracorporeal life support in adult patients. European Journal of Cardio-Thoracic Surgery. 2021;59(1):12-53. DOI: 10.1093/ejcts/ezaa283. PMID: 33097942.
Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA. 2009;301(17):1779-1789. DOI: 10.1001/jama.2009.600. PMID: 19417196.
Bouma W, Wijdh-den Hamer IJ, Koene BM, et al. Predictors of in-hospital mortality after mitral valve surgery for post-myocardial infarction papillary muscle rupture. Journal of Cardiothoracic Surgery. 2014;9:11. DOI: 10.1186/1749-8090-9-11. PMID: 24405651.
Connolly HM, Qian Q, Doyle BJ, et al. Outcomes of left ventricular thrombus after acute myocardial infarction in a contemporary cohort. Heart. 2023;109(10):773-779. DOI: 10.1136/heartjnl-2022-321932. PMID: 36781251.
Mehran R, Dangas GD, Weisbord SD. Contrast-associated acute kidney injury. New England Journal of Medicine. 2019;380(22):2146-2155. DOI: 10.1056/NEJMra1805256. PMID: 31141635.
Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022;327(7):662-675. DOI: 10.1001/jama.2022.0358. PMID: 35166796.